About Us

iNOVA4Health is a translational medicine programme organizing the efforts of biomedical researchers involved in i) biological understanding of disease, lead compounds and biopharmaceuticals pre-discovery, ii) technological scientists involved in preclinical development, and iii) clinicians involved in early clinical and first-in-man clinical trials from institutions within NOVA University of Lisbon. The programme will have a strong emphasis on developing therapies to promote healthy ageing and in targeting chronic diseases that are responsible for two thirds of deaths worldwide and a major burden on healthcare systems.


The aim of iNOVA4Health is to reinforce transdisciplinar and translational research activities amongst its four partners so as to implement precision medicine practices early on based on increasing knowledge of the mechanisms of disease.

The aim of this brochure is to bring into the Lisboa area translational medicine ventures substantially enlarging the existing “foot print” of today, reinforcing the strong thought – sharing and creative partnership culture of iNOVA4Health.


Global pharmaceutical companies and health biotechnology start-ups and SME’s willing to benefit from key resources available in Lisboa, coordinated by iNOVA4Health, for their discovery of new pharma models and clinical trial activities, accelerating bench-to-bedside practice.


The Lisboa area possesses a rich basic and applied medical research network, as well as very skilled multidisciplinary clinical teams, supervising access to patient.

The iNOVA4Health coordinates four key partners linked to Universidade NOVA de Lisboa:

  • iBET – Instituto de Biologia Experimental e Tecnológica (www.ibet.pt) is the largest private research team in Biotechnology in Portugal with a strong competence basis in discovery, development, production, purification and characterization of BIOPHARMACEUTICALS – cell and gene therapies, recombinant proteins, microbial and viral vaccines;
  • ITQB – Instituto de Biologia Química e Biologica (www.itqb.unl.pt) is a postgraduate and research institute in structural and molecular biology and biochemistry part of Univ. Nova de Lisboa (www.unl.pt).
  • NMS – NOVA Medical School (www.nms.unl.pt) research has a strong focus on studying molecular and cellular mechanisms of age related diseases and is the hub of a clinical research network based on the hospitals associated with the medical school.
  • IPOLFG – The Instituto Português de Oncologia de Lisboa Francisco Gentil (www.ipolisboa.min-saude.pt) is dedicated to the study, prevention and treatment of cancer, dealing with over 6000 new cases/year. It is a reference center for the management of esophageal, rectal and testicular neoplasia, pediatric oncology, and soft tissue and bone sarcomas. Research activities are focused in familial and individual cancer risk, genetics, epigenetics, tumor microenvironment and therapeutic modulation.

The programme is managed by iBET and the joint efforts will reach first-in-man applications, train clinicians, biochemists, biologists, engineers into a common practice of translational medicine, leading Portugal into the new paradigm of Personalized Medicine and healthy aging where human behavior, food and nutrition also play a role.

iNOVA4Health is cofunded by Fundação para a Ciência e Tecnologia / Ministério da Ciência e do Ensino Superior, through national funds, and by FEDER under the PT2020 Partnership Agreement.

Download Project Sheet here (only in Portuguese).

Project cofunded by: